Delighted to announce our latest investment in Oxford Endovascular, a spin-out from Oxford University, working to prevent brain haemorrhage by treating brain aneurysms, a condition that affects 1 in 50 persons. The investment was featured in the Times, read the article here.

London, 20th May 2024: Oxford Endovascular today announces the successful completion of an £8 million Series A+ funding round. The MedTech start-up, founded in 2015, is developing a novel approach to preventing brain haemorrhage by treating intracranial aneurysms.

Led by Parkwalk Advisors, the UK’s leading investor in university spinouts, this latest investment will help take its medical device, OXIFLOW, a step closer to a First-In-Human clinical study. The market opportunity for devices used to treat brain aneurysms is approaching $3 billion per year.

Inspired by the Japanese art of origami and using folding concepts from space-age technologies used in satellites, OXIFLOW, is being developed to improve patient outcomes for brain aneurysms – a condition that affects 1 in 50 people. OXIFLOW is a unique flow-diverter stent which is used to treat intracranial aneurysms at risk of rupture. The miniature device is laser-cut from Nitinol, an advanced nickel titanium alloy with superior memory and design capabilities.

Unlike conventional flow-diverters, OXIFLOW’s construction allows it to position and open more accurately and reliably. It is designed to conform to the patient’s blood vessels and reduce the risk of complications associated with current treatments. Up to 35 per cent of existing device placements for treating brain aneurysms today may have complications that can lead to adverse events.

This latest funding round will enable the company to accelerate OXIFLOW’s development, and further scale up its operations. The company has made significant technological progress since its previous investment round in 2021 and is now entering a pivotal period in its development, as it approaches human trials.

Mike Karim, CEO of Oxford Endovascular, said: “With the support of our investment partners, we are close to realising our vision of transforming brain aneurysm treatment. As we approach First-In-Human trials, our expert team is focused on working with regulators, physicians, and industry experts to bring this product to market and help tackle a condition that afflicts so many in the UK and worldwide.”

To date, Oxford Endovascular has also received financial backing in the form of grants from Horizon Europe, the EU’s key funding programme for research and innovation, and Innovate UK, the UK’s national innovation agency, as well as selection by the EU for its EIT-funded Covid rescue programme.

Alun Williams, Investment Director of Parkwalk Advisors, said: “We are proud to be playing a leading role in helping Oxford Endovascular unlock amazing design and engineering capabilities to tackle brain aneurysms. We are committed to backing research intensive companies that have the potential to make a difference via radical breakthroughs that will have a positive impact on society – Oxford Endovascular is the embodiment of this. This is a device we have backed from an early stage, that can improve lives, and it is demonstrative of the exceptional ideas currently spinning out of universities in the UK.”

Parkwalk Advisors first invested in Oxford Endovascular in 2015 and has invested a further £4.2 million in this Series A+ round. Other investors in the round include Norcliffe Capital, Oxford Science Enterprises (OSE), Vulpes and the University of Oxford – taking the combined fund raise to £8 million. It follows a £7.5 million Series A funding Round in April 2021.

To find out more about Oxford Endovascular, visit their website here or our portfolio page here.